Phio Pharmaceuticals Corp Net Income
| PHIO Stock | USD 0.86 0.07 7.53% |
As of the 6th of February, Phio Pharmaceuticals holds the Risk Adjusted Performance of (0.20), variance of 18.4, and Coefficient Of Variation of (353.34). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phio Pharmaceuticals, as well as the relationship between them.
Phio Pharmaceuticals Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.2 M | -8.6 M | |
| Net Loss | -8.2 M | -8.6 M | |
| Net Loss | -15.3 M | -16 M | |
| Net Loss | (0.82) | (0.86) | |
| Net Income Per E B T | 0.80 | 0.70 |
Phio | Net Income | Build AI portfolio with Phio Stock |
Evaluating Phio Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Phio Pharmaceuticals Corp's fundamental strength.
Latest Phio Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Phio Pharmaceuticals Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Phio Pharmaceuticals Corp financial statement analysis. It represents the amount of money remaining after all of Phio Pharmaceuticals Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Phio Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.15 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Phio Net Income Regression Statistics
| Arithmetic Mean | (10,532,713) | |
| Coefficient Of Variation | (30.68) | |
| Mean Deviation | 2,165,144 | |
| Median | (10,219,000) | |
| Standard Deviation | 3,231,237 | |
| Sample Variance | 10.4T | |
| Range | 13.8M | |
| R-Value | 0.37 | |
| Mean Square Error | 9.6T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | 236,661 | |
| Total Sum of Squares | 167.1T |
Phio Net Income History
Other Fundumenentals of Phio Pharmaceuticals Corp
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Phio Pharmaceuticals Net Income component correlations
Phio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Phio Pharmaceuticals is extremely important. It helps to project a fair market value of Phio Stock properly, considering its historical fundamentals such as Net Income. Since Phio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Phio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Phio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Phio diversify its offerings? Factors like these will boost the valuation of Phio Pharmaceuticals. Anticipated expansion of Phio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Phio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Phio Pharmaceuticals Corp's market price often diverges from its book value, the accounting figure shown on Phio's balance sheet. Smart investors calculate Phio Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Phio Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Phio Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phio Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Phio Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Phio Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Phio Pharmaceuticals.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Phio Pharmaceuticals on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Phio Pharmaceuticals Corp or generate 0.0% return on investment in Phio Pharmaceuticals over 90 days. Phio Pharmaceuticals is related to or competes with Transcode Therapeutics, Kiora Pharmaceuticals, In8bio, Biocardia, Aprea Therapeutics, Marker Therapeutics, and Galecto. Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States More
Phio Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Phio Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Phio Pharmaceuticals Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.29) | |||
| Maximum Drawdown | 19.15 | |||
| Value At Risk | (9.27) | |||
| Potential Upside | 4.88 |
Phio Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phio Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Phio Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Phio Pharmaceuticals historical prices to predict the future Phio Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.20) | |||
| Jensen Alpha | (1.30) | |||
| Total Risk Alpha | (1.42) | |||
| Treynor Ratio | (0.58) |
Phio Pharmaceuticals February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | (0.57) | |||
| Mean Deviation | 3.26 | |||
| Coefficient Of Variation | (353.34) | |||
| Standard Deviation | 4.29 | |||
| Variance | 18.4 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (1.30) | |||
| Total Risk Alpha | (1.42) | |||
| Treynor Ratio | (0.58) | |||
| Maximum Drawdown | 19.15 | |||
| Value At Risk | (9.27) | |||
| Potential Upside | 4.88 | |||
| Skewness | (0.64) | |||
| Kurtosis | 0.5345 |
Phio Pharmaceuticals Corp Backtested Returns
Phio Pharmaceuticals Corp maintains Sharpe Ratio (i.e., Efficiency) of -0.23, which implies the firm had a -0.23 % return per unit of risk over the last 3 months. Phio Pharmaceuticals Corp exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Phio Pharmaceuticals' Coefficient Of Variation of (353.34), variance of 18.4, and Risk Adjusted Performance of (0.20) to confirm the risk estimate we provide. The company holds a Beta of 2.12, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Phio Pharmaceuticals will likely underperform. At this point, Phio Pharmaceuticals Corp has a negative expected return of -0.9%. Please make sure to check Phio Pharmaceuticals' maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Phio Pharmaceuticals Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.16 |
Very weak predictability
Phio Pharmaceuticals Corp has very weak predictability. Overlapping area represents the amount of predictability between Phio Pharmaceuticals time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Phio Pharmaceuticals Corp price movement. The serial correlation of 0.16 indicates that over 16.0% of current Phio Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.16 | |
| Spearman Rank Test | 0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Phio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Phio Pharmaceuticals Corp reported net income of (7.15 Million). This is 102.1% lower than that of the Biotechnology sector and 110.21% lower than that of the Health Care industry. The net income for all United States stocks is 101.25% higher than that of the company.
Phio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phio Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phio Pharmaceuticals by comparing valuation metrics of similar companies.Phio Pharmaceuticals is currently under evaluation in net income category among its peers.
Phio Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Phio Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Phio Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Phio Pharmaceuticals' value.| Shares | Barclays Plc | 2025-03-31 | 5.0 | Tower Research Capital Llc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-03-31 | 0.0 | Ubs Group Ag | 2025-06-30 | 0.0 | Xtx Topco Ltd | 2025-06-30 | 0.0 | Hrt Financial Llc | 2025-03-31 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 57.7 K | Vanguard Group Inc | 2025-06-30 | 48.7 K | Cetera Investment Advisers | 2025-06-30 | 32.5 K | Virtu Financial Llc | 2025-06-30 | 14.3 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 6 K |
Phio Fundamentals
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | 1.49 M | ||||
| Shares Outstanding | 11.04 M | ||||
| Shares Owned By Insiders | 7.58 % | ||||
| Shares Owned By Institutions | 18.43 % | ||||
| Number Of Shares Shorted | 475.27 K | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 48.01 X | ||||
| Gross Profit | (3.59 M) | ||||
| EBITDA | (7.38 M) | ||||
| Net Income | (7.15 M) | ||||
| Cash And Equivalents | 18.02 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (7.11 M) | ||||
| Short Ratio | 2.57 X | ||||
| Earnings Per Share | (2.09) X | ||||
| Target Price | 14.0 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 15.79 M | ||||
| Total Asset | 5.74 M | ||||
| Retained Earnings | (146.36 M) | ||||
| Working Capital | 4.72 M | ||||
| Current Asset | 9.23 M | ||||
| Current Liabilities | 2.17 M | ||||
| Net Asset | 5.74 M |
About Phio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phio Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phio Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Phio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Phio Stock
Moving against Phio Stock
| 0.81 | DSGN | Design Therapeutics | PairCorr |
| 0.66 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.63 | ENGN | enGene Holdings Common | PairCorr |
| 0.61 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.37 | ALT | Altimmune | PairCorr |
The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Biotechnology sector continue expanding? Could Phio diversify its offerings? Factors like these will boost the valuation of Phio Pharmaceuticals. Anticipated expansion of Phio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Phio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Phio Pharmaceuticals Corp's market price often diverges from its book value, the accounting figure shown on Phio's balance sheet. Smart investors calculate Phio Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Phio Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Phio Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phio Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.